The promising role of this APα therapy in AD and PD is supported by the recent work that peripheral administration of APα, with its ability to permeate the blood brain barrier, could improve cognitive and motor performance and increase the number of DA neurons in the SN of mice lesioned by MPTP and mice with AD mutations. The gene discussed is ENPEP; the disease is Alzheimer disease.